Previous 10 | Next 10 |
BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, will present new data today about RTB101, the company’s i...
BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 2019 Cantor...
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, has been selected to present new data from its clinical develop...
Adamas Pharmaceuticals (NASDAQ: ADMS ) initiated with Neutral rating and $8 (50% upside) price target at Cantor Fitzgerald. More news on: Adamas Pharmaceuticals, Inc., Covetrus, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...
resTORbio (NASDAQ: TORC ): Q2 GAAP EPS of -$0.51 misses by $0.12 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 – BOSTON, Aug. 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company...
BOSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the company will present a corporate overview at ...
resTORbio, Inc. ( TORC ) is a clinical-stage, specialty biopharmaceutical company. They are developing medicines that target the biology of aging to prevent or treat aging-related diseases. The company's lead product candidate, RTB101, is an orally administered, selective, and potent inhibit...
– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – BOSTON, July 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ...
News, Short Squeeze, Breakout and More Instantly...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...